Company / Revenue
ELITE PHARMACEUTICALS INC /NV/ Revenue History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$84.0M
FY2024
5-year range
$32.3M / $84.0M
FY2020-FY2024
Trend
+48.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has increased for 7 consecutive years, from $7M in FY2017 to $84M in FY2024.
Based on SEC 10-K filings.
$84M in FY2024 with a 5-year CAGR of +36.1%.
Improved from $34M to $84M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +37.6%
- 5-Year CAGR
- +36.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- ELITE PHARMACEUTICALS INC /NV/'s revenue has grown for 7 consecutive years.
- 5-year CAGR of +36.1%, indicating consistent growth.
- In FY2024, revenue increased 48.4% year-over-year.
- Lowest revenue in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $84.0M | +48.4% |
| FY2023 | $56.6M | +65.8% |
| FY2022 | $34.2M | +5.9% |
| FY2021 | $32.3M | +27.1% |
| FY2020 | $25.4M | +41.0% |
| FY2019 | $18.0M | +137.8% |
| FY2018 | $7.6M | +1.5% |
| FY2017 | $7.5M | -22.6% |
| FY2016 | $9.6M | -22.9% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026